May 26 |
Wall Street Breakfast: The Week Ahead
|
May 25 |
Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo
|
May 23 |
Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors
|
May 22 |
3 Biotech Stocks to Buy Now: May 2024
|
May 22 |
Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024
|
May 20 |
Gilead touts additional data on liver disease asset seladelpar ahead of PDUFA date
|
May 20 |
Gilead's Recently Acquired Liver Disease Candidate Shows Improvements In Disease Progression And Associated Itch
|
May 19 |
Biopharma M&A surges year over year in Q1
|
May 18 |
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
|
May 17 |
Private Equity Prowl: 3 Overlooked Stocks Primed for Buyout Bids
|